Essential details
Shipping:Express Delivery
Product Introduction
Fuzeraxib is an irreversible KRAS G12C inhibitor that exhibits synergistic anti-cancer effects with cetuximab (HY-P9905).
| Boiling point | 819.5 ± 65.0 ° C (Predicted) |
| Density | 1.49 ± 0.1g/cm3 (Predicted) |
| Form | Solid |
| Acidity coefficient (pKa) | 6.74 ± 0.35 (Predicted) |
| Color | Lightyellow to yellow |